Moderna’s 2022 Shot Orders Edge Up Amid Easing Pandemic
(Bloomberg) -- Orders for Moderna Inc.'s Covid-19 vaccine rose only modestly in the last six weeks as it battles rivals for market share amid fading pandemic concerns, although the company is still waiting to see whether the U.S. places new booster orders for later this year.
The messenger RNA vaccine maker said it has signed $19 billion worth of agreements for 2022 sales of its shot, up from $18.5 billion announced in January. But the company also said in an quarterly earnings statement that options for 2022 orders were $3 billion, down from $3.5 billion announced earlier.Â
Still, Chief Executive Officer Stephane Bancel said on a conference call that the U.S. government has yet to put in new orders for 2022. That suggests there is room for the numbers to grow later this year if the U.S. decides to buy a large amount of booster doses.
Moderna also announced a $3 billion share repurchase program. The shares rose as much as 12% as of 10:09 a.m. in New York. They had lost almost half their value before today since the year began.
Covid case numbers are plummeting around the world as the omicron wave recedes, while new vaccine makers such as Novavax Inc. enter the market. As countries relax pandemic restrictions, Moderna is working to retain momentum in sales of its only product.
For the quarter, earnings were $11.29 a share on revenues of $7.21 billion. Analysts had estimated earnings of $10.17 a share and revenue of $6.84 billion. The company said final 2021 sales of its Covid vaccine, its only product, were $17.7 billion, slightly above the $17.5 billion preliminary product sales number announced in January.
Moderna has been racing with rival mRNA partners Pfizer Inc. and BioNTech SE to ramp up Covid vaccine production and sell shots around the world. Pfizer has said it has $32 billion in 2022 orders for its Covid vaccine.
Key variables in Moderna's future sales include whether fourth doses will be widely used and whether variant-specific boosters, which both Moderna and Pfizer are testing, will prove useful. On a conference call with analysts, Moderna officials said they continue to believe that a fourth booster dose will be needed by the fall of 2022.
Moderna also said it's working on a shot that would combine its existing Covid vaccine with the omicron-specific version that's in testing.
Overall, about 807 million vaccine doses were shipped worldwide in 2021, Moderna said.
©2022 Bloomberg L.P.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.